Endo International — Corporate Update (February 2023)
19 slides from Endo International's corporate update, Feb 14, 2023
Slide 1: Long Term Plan Update February 13, 2023
Long Term Plan Update February 13, 2023 Cleansing Material Preliminary and Subject to Material Change Exhibit 99.1
Slide 2: Table of Contents
Table of Contents 2022A Unaudited Results Feb 2023 Long Term Plan Feb 2023 Segment Projections
Slide 3: 2022A results exceeded expectations
2022A results exceeded expectations 2022A vs July LBE Highlights 2022A total revenue exceeded expectations primarily driven by Varenicline (delayed competition), partially offset by lower-than-expected Xiaflex revenue due to the 2H22 disruption from a 3rd party specialty pharmacy provider transition
Slide 4: 2022A ending cash exceeded expectations
2022A ending cash exceeded expectations 2022A vs July LBE Highlights 2022A pre-tax uFCF exceeded expectations primarily due to better-than-expected Varenicline revenue (delayed competition) and lower than expected OPEX and 1x payments. 2022A Litigation/Advisors was favorable due to lower-than-expect
Slide 5: Table of Contents
Table of Contents 2022A Unaudited Results Feb 2023 Long Term Plan Feb 2023 Segment Projections
Slide 6: There are several key assumptions underpinning the Feb 2023 LTP
There are several key assumptions underpinning the Feb 2023 LTP Xiaflex revenue is expected to grow to over $700M in 2027 (2023-27 CAGR of 10%) driven by an expected recovery from 2H22 disruption and continued strong response to planned advertising and promotion investment in on-market indications a
Slide 7: Revenue growth will be driven by Xiaflex and the Sterile pipeline
Revenue growth will be driven by Xiaflex and the Sterile pipeline Branded Specialty Products growth is expected to be driven by continued growth in Xiaflex resulting from ongoing promotional spend to increase diagnosis and treatment rates and improving market conditions. Sterile Injectables growth i
Slide 8: Consistently high gross margins are expected over the forecast horizon
Consistently high gross margins are expected over the forecast horizon Branded gross profit increases as Xiaflex increases; however, GM% remains relatively flat as higher margin specialty products are offset by erosion of Established brands. Sterile gross profit and GM% decrease as Vasostrict and Ad
Slide 9: EBITDA and unlevered FCF are expected to grow significantly faster than revenue
EBITDA and unlevered FCF are expected to grow significantly faster than revenue over the next 5 years Revenue growth is primarily driven by Xiaflex and the SI pipeline. High gross margins remain stable overtime and reflect shift in product mix and benefit from manufacturing efficiencies through on-g
Slide 10: Revenue and EBITDA growth is expected to be driven by Branded and Sterile segments
Revenue and EBITDA growth is expected to be driven by the Branded and Sterile segments Branded growth is expected to be driven by growth in Xiaflex on-market indications (PD and DC) and the launch of new indications (PF). Sterile Injectables growth in 2025 is expected to be driven by a significant n
Slide 11: The LTP reflects uncertainties related to several opportunities and risks
The LTP reflects uncertainties related to several opportunities and risks Area Key Opportunity Key Risk Xiaflex PD+DC Faster than expected near-term rate of demand growth Slower than expected rate of growth Varenicline Fewer than expected competitors enter the market US market volumes fully return t
Slide 12: Table of Contents
Table of Contents 2022A Unaudited Results Feb 2023 Long Term Plan Feb 2023 Segment Projections
Slide 13: The Branded portfolio is expected to deliver solid and sustainable revenue and EBITDA growth
The Branded portfolio is expected to deliver solid and sustainable revenue and EBITDA growth Revenue growth is expected to be driven by continued growth in Xiaflex on-market and pipeline indications and will be offset by continued erosion of the Other Specialty and Established Brands portfolio mainl
Slide 14: The Sterile Injectables pipeline has the potential to deliver solid growth
The Sterile Injectables pipeline has the potential to deliver solid growth Sterile Injectables decline through 2023 is primarily driven by the decline in Vasostrict; however, 2023-27 growth is expected from the launch of ready-to-use and other differentiated pipeline products that are in development
Slide 15: Generics revenue and EBITDA is expected to decline
Generics revenue and EBITDA is expected to decline as a result of limited growth investment in the portfolio Generics revenue is expected to decline as existing key products (Lubiprostone and Varenicline) lose exclusivity/face competition. Varenicline could potentially provide meaningful upside depe
Slide 16: The International portfolio is expected to grow
The International portfolio is expected to grow International revenue expected to remain relatively flat through 2024 and then grow as a result of product launches in 2022-23 (i.e., Xydalba – antibacterial and Cenobamate – epilepsy). OPEX is expected to remain relatively flat as current infrastructu
Slide 17: Appendix
Appendix
Slide 18: ~40 new Sterile product candidates are in development and expected to launch over next 5 years
~40 new Sterile product candidates, of which > 60% are RTU products, are in development and expected to launch over the next 5 years Projects typically require 3-5 years from initiation to launch. A robust process exists to continuously identify, screen and evaluate potential new opportunities to ad
Slide 19: OPEX as % of sales is in-line with peer benchmarks
OPEX as % of sales is in-line with peer benchmarks The benchmarks represent the 1st quartile, average and 3rd quartile across 17 peer companies over the 2020-22 period. Peers include a mix of commercial stage specialty branded, sterile and generic companies (mix intended to capture mix of Endo’s bus
Endo International — Corporate Update (February 2023) on 6ix